<code id='EF13845325'></code><style id='EF13845325'></style>
    • <acronym id='EF13845325'></acronym>
      <center id='EF13845325'><center id='EF13845325'><tfoot id='EF13845325'></tfoot></center><abbr id='EF13845325'><dir id='EF13845325'><tfoot id='EF13845325'></tfoot><noframes id='EF13845325'>

    • <optgroup id='EF13845325'><strike id='EF13845325'><sup id='EF13845325'></sup></strike><code id='EF13845325'></code></optgroup>
        1. <b id='EF13845325'><label id='EF13845325'><select id='EF13845325'><dt id='EF13845325'><span id='EF13845325'></span></dt></select></label></b><u id='EF13845325'></u>
          <i id='EF13845325'><strike id='EF13845325'><tt id='EF13845325'><pre id='EF13845325'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:knowledge    Page View:1742
          the shape of a medical note connected by dots and lines — health tech coverage from STAT
          Adobe

          In recent months, the federal government has repeatedly told Medicare Advantage insurers that they cannot use artificial intelligence or algorithms to deny medical services the government routinely covers.

          But in finalizing a rule to that effect, it also stepped into a thicket of questions from insurers about a technology that is especially difficult to pin down: What is AI? Can it be used at all to make decisions about the coverage of older patients? If so, how?

          advertisement

          This week, the federal agency that oversees Medicare sought to boil it all down into a simple directive: Put the circumstances of the individual patient first, and your algorithm second.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted
          FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

          DarronCummings/APScientistsattheFoodandDrugAdministrationhavetwobigquestionsaboutEliLilly’sexperimen

          read more
          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more

          FDA has safety concerns on CRISPR

          AdobeTheFoodandDrugAdministrationsaidonFridaythatithassomesafetyconcernsaboutanexperimentalCRISPR-ba